The 2 major functions of the ex vivo platform are:

- To organize and centralize the provision of fresh samples to the medico-scientific community
- To conduct tests on tumor slices to predict the response to therapeutic agents.

**Major scientific expertise: “Ex vivo” predictive tests**

This innovative technique evaluates the sensitivity of tumor cells to a given treatment by analyzing proliferation (Ki67) and apoptosis (PARP).

To this end, 250 µm-thick tumor sections are cut and cultured in appropriate medium for 48h with the tested agent. At the end of the treatment slices are fixed and paraffin embedded before being analyzed by immunohistochemistry (1 slice can be divided into 10-20 samples). Supernatant can also be collected.

**Major technological expertise: Slicing fresh samples**

This innovative bench unit with vibrating blade has been designed to cut fresh tissue slices. The platform uses this instrument to prepare tumor sections that will be analyzed in ex vivo predictive tests. However it can also be used for other experimental purposes.

**Logistics support**

CMT (medico-technical committee) review

Ex-vivo Platform

Surgery

Pathology

Ex-vivo Platform

Biological Resources Center

Validation of Patient Consent

Conservation of samples

Research teams
Access details

- Basic science projects
- Translational projects
- Preclinical projects
- Animal samples
- Human samples

Mention us in your publications!

To allow our platform to pursue its objectives, we need you to mention our work in your publications as follows:
Plateforme Ex vivo, Département de recherche translationnelle et d’innovations, Centre Léon Bérard, Lyon, France.
Fondation Synergie Lyon Cancer, Lyon, France.

Project workflow

Initial consultation
(e-mail: Séverine Tabone-Eglinger)

Filing of submission form

Review of the project by the medico-technical committee (CMT) of the CLB

If authorized

“Fresh sample” project
“Ex vivo” predictive test

Anonymized weekly planning sent to research teams
D-Day: test conducted by the platform

D-Day: Research teams informed of the sample availability
Ex vivo results reporting

Séverine Tabone-Eglinger
– Scientific director

Séverine Tabone-Eglinger has high experience in handling fresh tumor as she coordinated the IMODI project, developing Patient Derived Xenograft mouse models.
She is also responsible for the biological resources center and member of the committee reviewing all sample requests (CMT). She will help you to set up your project verifying respect of regulatory measures, and evaluating coordination needs with other facilities.

Sophie Léon
– Platform manager

Sophie Léon is a laboratory technician with a strong expertise in histological techniques.
Her technical skills include fresh tumor slicing and conducting organotypic cultures.

Contacts
CENTRE LÉON BÉRARD
Département de Recherche Translationnelle et Innovation
Cheney B building, 3rd floor
28, rue Laennec - F-69008 Lyon
severine.tabone-eglinger@lyon.unicancer.fr